Also, Bank of America’s fight during the proxy-voting season and Tesla’s likely signal that it’s now focusing on profits.

Also, Netflix and Disney’s edge against their rivals.

Plus, 5 gold-rated and 2 silver-rated funds that investors should consider adding to their portfolios.

Also, the factors that helped lift Morningstar’s suggested starting safe withdrawal rate.

Also, Morningstar forecasts five interest rate cuts in 2024, and why Adobe’s outlook is slightly disappointing.

The founder of Her First $100K explains the importance of loud budgeting, pay transparency, and teaching girls about money.

Also, Salesforce’s dividend plans and Snowflake’s outlook following its leadership change.

Plus, what will Vanguard do in 2024, and are Home Depot, Nvidia and Walmart stocks a buy right now?

The fixed-income side of your 60/40 portfolio may need an overhaul.

Plus, details about Ford’s special dividend for 2024, and how spot bitcoin ETFs performed in their first month.

Plus, Meta’s stock surprise, and how to avoid making these 3 investing mistakes.

Plus, how much does an ETF really cost, and are Tesla, Netflix and Verizon stocks a buy right now?

Also, the potential hit on Boeing’s stock value in the wake of its safety troubles.

Also, what you should know before buying a spot bitcoin ETF.

Plus, why 2024 will likely be a challenging year for the industry, and 3 stock opportunities.

Plus, the outsized role of the Magnificent Seven stocks in active fund managers’ portfolios.

Plus, six trends that could affect markets in 2024.

Plus, what the holiday shopping season could reveal about consumer spending in 2024.   

Salesforce and Snowflake stocks are cheap, but Intuit stock is expensive, plus, we tell you why active ETFs are all the rage right now.

Plus, what investors should watch for at COP28 and the outlook for Nvidia stock.

Also, Morningstar’s rankings of the best health savings account providers and a breakdown of the HSA triple-tax advantage.

Also, slowing inflation opens the door for interest-rate cuts next year.

Also, the sales outlook for the blockbuster diabetes drug, Mounjaro, and the debate on whether unions are bad for investors.

Plus, insights on Alphabet and Amazon’s stocks and the potential signal leading to interest-rate cuts.